Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$0.55 USD
-0.03 (-5.21%)
Updated Aug 8, 2024 03:58 PM ET
After-Market: $0.55 0.00 (0.00%) 6:00 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Monopar Therapeutics Inc. [MNPR]
Reports for Purchase
Showing records 1 - 20 ( 51 total )
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Progress in Camsirubicin and MNPR-101 Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Promising Early Efficacy in Camsirubicin Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Camsirubicin Dose Escalating with Promising Response, Pipeline Advancing
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Dose Response with 650 mg/m2 Dose in ASTS Trial
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
CSI Singapore Collaboration to Evaluate Radiolabeled MNPR-101 in Cancers
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Phase 1b Trial Update of Camsirubicin Promising, Enhances Our Optimism
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Camsirubicin Phase 1b Trial Advancing, MNPR101 RIT Preclinical Data Promising
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Camsirubicin Dose-Escalation Going Well; Lower $2.00 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Validive Not Viable Based on Phase 2b Readout, Focus on Camsirubicin
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Camsirubicin Study Progressing to Next Stage; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Enhancing Clinical Outcomes in Cancer Patients - Resume Buy, $18 PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Monopar Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Spotlight on VOICE Readout in 1Q23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S